Identification of C1qTNF-related protein 4 as a potential cytokine that stimulates the STAT3 and NF-κB pathways and promotes cell survival in human cancer cells

Cancer Letters

Volumn 308, Issue 2, 2011, Pages 203-214

  Li, Qi ^a,b   Wang, Lanlan ^a,b   Tan, Weifeng ^a,b   Peng, Zhi ^a,b   Luo, Yang ^a,b   Zhang, Yingmei ^a,b   Zhang, Guoying ^a,b   Na, Daxiang ^a,b   Jin, Peng ^a,b   Shi, Taiping ^a,b   Ma, Dalong ^a,b   Wang, Lu ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Cancer related inflammation; Cancer therapy; CTRP4; IL6 STAT3; NF B

Indexed keywords

COMPLEMENT COMPONENT C1Q TUMOR NECROSIS FACTOR RELATED PROTEIN 4; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN HEPG2; CELL STRAIN HT29; CELL SURVIVAL; CONTROLLED STUDY; CTRP4 GENE; GENE; HUMAN; HUMAN CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; BASE SEQUENCE; CYTOKINES; FLOW CYTOMETRY; HEK293 CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; STAT3 TRANSCRIPTION FACTOR;

EID: 79959548495     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.005     Document Type: Article

References (41)

1. Schaffler A., Scholmerich J., Salzberger B. Adipose tissue as an immunological organ: toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 2007, 28:393-399.
2. Kishore U., Gaboriaud C., Waters P., Shrive A.K., Greenhough T.J., Reid K.B., Sim R.B., Arlaud G.J. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol. 2004, 25:551-561.
3. Wong G.W., Krawczyk S.A., Kitidis-Mitrokostas C., Ge G., Spooner E., Hug C., Gimeno R., Lodish H.F. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J. 2009, 23:241-258.
4. Lee W., Kim M.J., Park E.J., Choi Y.J., Park S.Y. C1qTNF-related protein-6 mediates fatty acid oxidation via the activation of the AMP-activated protein kinase. FEBS Lett. 2010, 584:968-972.
5. Jeon J.H., Kim K.Y., Kim J.H., Baek A., Cho H., Lee Y.H., Kim J.W., Kim D., Han S.H., Lim J.S., Kim K.I., Yoon do Y., Kim S.H., Oh G.T., Kim E., Yang Y. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008, 22:1502-1511.
6. Correa P. The epidemiology of gastric cancer. World J. Surg. 1991, 15:228-234.
7. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-50.
8. Porschen R., Strohmeyer G. Risk of colorectal cancer in ulcerative colitis - monitoring strategies and identification of risk patients. Z Gastroenterol. 1992, 30:585-593.
9. Balkwill F., Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin. Pharmacol. Ther. 2010, 87:401-406.
10. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
11. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M., Kollias G., Balkwill F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999, 5:828-831.
12. Lu T., Stark G.R. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle 2004, 3:1114-1117.
13. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006, 25:409-416.
14. Akira S., Taga T., Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 1993, 54:1-78.
15. Cavarretta I.T., Neuwirt H., Untergasser G., Moser P.L., Zaki M.H., Steiner H., Rumpold H., Fuchs D., Hobisch A., Nemeth J.A., Culig Z. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007, 26:2822-2832.
16. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
17. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
18. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C., Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
19. Sehgal P.B. Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells. Oncogene 2010, 29:2599-2600. (author reply 2601-2593).
20. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., Moser P.L., Fuchs D., Hobisch A., Culig Z. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Relat. Cancer 2009, 16:155-169.
21. Wong B.C., Jiang X., Fan X.M., Lin M.C., Jiang S.H., Lam S.K., Kung H.F. Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003, 22:1189-1197.
22. Higashitsuji H., Nagao T., Nonoguchi K., Fujii S., Itoh K., Fujita J. A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis. Cancer Cell 2002, 2:335-346.
23. Schichl Y.M., Resch U., Hofer-Warbinek R., de Martin R. Tristetraprolin impairs NF-kappaB/p65 nuclear translocation. J. Biol. Chem. 2009, 284:29571-29581.
24. Ara T., Song L., Shimada H., Keshelava N., Russell H.V., Metelitsa L.S., Groshen S.G., Seeger R.C., DeClerck Y.A. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 2009, 69:329-337.
25. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
26. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
27. Rowley M., Van Ness B. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response. Oncogene 2002, 21:8769-8775.
28. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
29. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., Anderson K.C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 1997, 159:2212-2221.
30. Nakafuku M., Satoh T., Kaziro Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin-6, induce an accumulation of an active Ras.GTP complex in rat pheochromocytoma PC12 cells. J. Biol. Chem. 1992, 267:19448-19454.
31. Pengju Z., Weiwen C., Aiying W., Zhaobo C., Nana N., Zhaoqin H., Qingwei L., Anli J. NKX3.1 potentiates TNF-alpha/CHX-induced apoptosis of prostate cancer cells through increasing caspase-3 expression and its activity. Biochem. Biophys. Res. Commun. 2010, 398:457-461.
32. Emmanouil-Nikoloussi E.N., Nikoloussis E., Manthou M.E., Goula O., Likartsis C., Papamitsou T., Frangou H., Massouridou S., Lazaridis C., Manthos A. Breast tumor developed in a pregnant rat after treatment with the teratogen Cycloheximide. Hippokratia 2010, 14:136-138.
33. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
34. Li Y., Du H., Qin Y., Roberts J., Cummings O.W., Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 2007, 67:8494-8503.
35. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
36. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
37. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
38. Martignoni M.E., Kunze P., Hildebrandt W., Kunzli B., Berberat P., Giese T., Kloters O., Hammer J., Buchler M.W., Giese N.A., Friess H. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res. 2005, 11:5802-5808.
39. Bollrath J., Greten F.R. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009, 10:1314-1319.
40. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
41. Liu Y., Li P.K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem. 2010, 285:27429-27439.